Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since May 18 · below the Ichimoku cloud · RSI 28 (oversold) · MACD below its signal · 9% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $133.2K | 0.00% | 21.77K | −33% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VRCA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.4 | -22.2 | -3.3 | 20.4 | -9.6 | 6.2 | -14.7 | 4.6 | -12.2 | -25.3 | −56.9% | ||
| 2025 | -7.4 | 0.2 | -31.9 | 5.0 | 6.7 | 7.1 | 6.2 | -0.6 | -23.0 | -16.2 | 152.1 | -8.7 | +18.7% |
| 2024 | -22.8 | -6.7 | 12.3 | 17.7 | 22.2 | -14.3 | -9.6 | -64.3 | -38.3 | -3.4 | -8.6 | -45.3 | −90.4% |
| 2023 | 68.0 | 67.7 | -16.1 | -5.1 | -8.1 | 1.8 | 1.2 | -22.1 | -14.6 | -5.3 | 0.0 | 98.9 | +166.2% |
| 2022 | -10.6 | 2.3 | -3.2 | -19.0 | -70.6 | -0.5 | 64.1 | 24.4 | -25.5 | -14.7 | 30.5 | -15.4 | −70.0% |
| 2021 | 2.1 | 16.7 | 10.5 | -12.9 | -14.7 | 0.4 | -5.3 | 4.7 | 11.6 | 0.7 | -17.8 | -11.5 | −20.4% |
| 2020 | -8.7 | -18.2 | -7.9 | 10.4 | -4.9 | -4.1 | -40.4 | 40.1 | -15.8 | -4.3 | 23.5 | 25.8 | −27.6% |
| 2019 | 46.9 | -5.4 | -4.5 | -7.5 | -28.7 | 63.0 | 5.3 | -19.0 | 48.9 | -8.4 | 11.5 | 5.4 | +95.0% |
| 2018 | -11.8 | 1.1 | -7.7 | -18.8 | -9.1 | -32.1 | −58.7% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 17, 2026 | Kirby John J.Chief Financial Officer | Purchase at price 4.93 per share. | 5K | $24.65K |
| Aug 17, 2026 | Rosenberg Noah LOfficer | Purchase at price 4.91 - 4.92 per share. | 6.2K | $30.61K |
| Aug 16, 2026 | Rieger JaysonChief Executive Officer | Purchase at price 4.91 - 5.06 per share. | 25K | $125.75K |
| Aug 16, 2026 | Zawitz DavidChief Operating Officer | Purchase at price 4.98 per share. | 6K | $29.88K |
| Dec 22, 2025 | Kirby John J.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Nov 24, 2025 | Rieger JaysonChief Executive Officer | Purchase at price 4.24 per share. | 94.3K | $400.11K |
| Nov 24, 2025 | Zawitz DavidChief Operating Officer | Purchase at price 4.24 per share. | 10K | $42.42K |
| Nov 24, 2025 | Manning Paul B.Director and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 4.24 per share. | 4.13M | $17.51M |
| Nov 24, 2025 | Kirby John J.Chief Financial Officer | Purchase at price 4.24 per share. | 3.5K | $15.00K |
| Nov 24, 2025 | Rosenberg Noah LOfficer | Purchase at price 4.24 per share. | 2.4K | $10.00K |
| Mar 16, 2025 | Hayes Christopher GOfficer | Sale at price 0.65 per share. | 4.3K | $2.81K |
| Nov 25, 2024 | Manning Paul B.Director and Beneficial Owner of more than 10% of a Class of Security | Stock Gift at price 0.00 per share. | 450K | — |
| Nov 21, 2024 | Rieger JaysonChief Executive Officer | Purchase at price 0.99 per share. | 280.9K | $279.35K |
| Nov 21, 2024 | Manning Paul B.Director and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 0.99 per share. | 22.92M | $22.80M |
| Nov 21, 2024 | Stalfort John ADirector | Purchase at price 0.99 per share. | 1.12M | $1.12M |
| Nov 5, 2024 | Kirby John J.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 54.3K | — |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Buy / hold / sell counts